After falling for three straight years on declining sales of hepatitis C drugs, Gilead Sciences’ (GILD) revenues finally seemed to bottom last year, and even resumed growing again. Now there’s hope that the global coronavirus pandemic could give Gilead an additional financial shot in the arm in 2020 and beyond.In a note surveying the “medical view from the front lines” on COVID-19 developments, Cowen analyst Steve Scala sketched out what one hopes will turn out to be the worst case scenario for coronavirus in the U.S.: Peak infections of 100,000 patients — a bit more than China suffered during its …read more
Source:: Yahoo Finance
